Photo by nci from unsplash
The TOPCAT trial, overall, showed no benefit for spironolactone in heart failure patients with preserved ejection fraction (HFpEF). Post-hoc, spironolactone helped participants from the Americas but not Eastern Europe, potentially… Click to show full abstract
The TOPCAT trial, overall, showed no benefit for spironolactone in heart failure patients with preserved ejection fraction (HFpEF). Post-hoc, spironolactone helped participants from the Americas but not Eastern Europe, potentially due to differences in baseline characteristics or adherence. We
Keywords:
identify hfpef;
composite metric;
hfpef patients;
benefit spironolactone;
hfpef;
metric identify
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!